To increase its clinical genomics capabilities, Abu Dhabi-based AI health-tech firm G42 Healthcare is joining Saphetor SA, a Swiss precision medicine business and developer of the VarSome suite of bioinformatics tools.
In addition to enhancing the UAE’s standing as a centre for global innovation and clinical genomics research, the collaboration will promote the health of future generations, according to a statement, by enabling biologists, geneticists, and physicians to push the limits of healthcare innovation and discovery. Enhancing these new capabilities is part of G42 Healthcare’s mission to provide insights and facilitate early diagnosis and treatment of cancer, rare and metabolic diseases, and other regional genetic conditions. The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies with the shortest turnaround time. This collaboration also enables clinical genomics, at scale, as a service, using G42 Healthcare’s three genomic sequencing platforms offering both extended and short-read capabilities.
A few insights by great minds!
“VarSome is a precious resource to support clinical decisions and for clinical genomics research in delivering comprehensive genome data, biological insights, and healthcare outcomes for better personalized and preventive healthcare delivery,” said Andreas Massouras, CEO and founder at Saphetor SA.
Andreas Massouras, CEO and Founder of Saphetor SA, said: “Since its inception, Saphetor has been committed to enabling accurate molecular diagnosis at scale for a wide range of disorders through identification and interpretation of human genomic variants by leveraging proprietary algorithms and expert domain knowledge. VarSome is a precious resource to support clinical decisions and clinical genomics research in delivering comprehensive genome data, biological insights, and healthcare outcomes for better personalized and preventive healthcare delivery. At Raptor, we are all excited for our technology to serve the people of the UAE and beyond via our partnership with G42 Healthcare”.
G42 Healthcare’s goal is to aid in the early identification and treatment of cancer, rare and metabolic disorders, and other genetic conditions in the area. The business just released over 250 comprehensive clinical genetic testing panels with the quickest turnaround times, utilizing sequencing technologies. The statement noted that the three genomic sequencing systems offered by G42 that support long and short reads are used in this cooperation to provide clinical genomics at scale as a service.
“The collaboration will fortify G42 Healthcare’s clinical genomics solutions by leveraging the VarSome suite of bioinformatics tools to deliver valuable data insights and improved outcomes. This partnership is a pivotal step in our efforts to reinforce UAE’s reputation as the regional hub of innovation in healthcare and life sciences,” said Ashish Koshy, CEO of G42 Healthcare.
About Author
